MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • SARS-CoV-2 Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • SARS-CoV-2 Vaccine
    • Publications
  • News & Media
  • Contact Us
    • Contact Us
    • Careers
  •  
  • Contact Us
  • Careers


AIVITA Biomedical is a biotechnology company developing personalized vaccines that target COVID-19 and the seed of all cancers using our autologous cell platform. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development in cancer, infectious disease and other fields.

Recent News

  • AIVITA Biomedical Appoints Dr. H. Christian Fibiger to its Board of Directors
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote at Festival of Biologics
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote At Vaccine World Asia Congress
  • AIVITA Biomedical CEO Dr. Hans Keirstead to Chair Keynote Panel and Deliver Talk at World Immunotherapy Congress Europe
  • AIVITA Biomedical’s Stem Cell-Derived Retina Transplant Restores Vision Loss in Preclinical Study

Site Navigation

  • About Us
  • Programs
  • News & Media
  • Contact Us
Copyright © 2020 | AIVITA Biomedical, Inc.